Therapeutics for Women%s Health: Technologies and Global Markets
NEW YORK, June 10, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Therapeutics for Women%s Health: Technologies and Global Markets
http://www.reportlinker.com/p02158721/Therapeutics-for-Women%s-Health-Technologies-and-Global-Markets.html
Use this report to:
- Learn about the main women's health disorders and relevant disease prevalence population.
- Identify the impact of demographic, economic, and other factors that will drive future demand for the women's health therapeutics market.
- Assess the long-term outlook for women's health therapeutics, taking into account market opportunities, as well as technological and financial factors.
- Identify leading drug manufacturers and receive analysis on the structure of the women's health therapeutics industry.
Highlights
- The global market for women's health therapeutics was worth nearly $18.3 billion in 2012. The market is expected to increase from nearly $19 billion in 2013 to nearly $22.5 billion by 2018, a compound annual growth rate (CAGR) of 3.5% for the five-year period, 2013 to 2018.
- In 2012, the U.S. accounted for about 56% of the women's health therapeutics market, or $10.2 billion. This market is expected to increase from nearly $10.8 billion in 2013 to $13.5 billion by 2018, a CAGR of 4.7% from 2013 to 2018.
- Europe accounted for about 37% of the total market, or about $6.8 billion in 2012. This market is expected to increase from $6.9 billion in 2013 to $7.5 billion by 2018, CAGR of
1.7% from 2013 to 2018.
INTRODUCTION
Women's health disorders include health issues unique and specific to the female gender. Women's health concerns have gained significant attention in recent times due
to disease pattern (illness, symptoms and response) and treatment differences between men and women. Gynecological and musculoskeletal disorders are considered
the key areas of focus within the women's health disorder market. Menopause, postmenopausal osteoporosis, endometriosis and polycystic ovary
syndrome (PCOS) are the most common issues within women's health. Menopause is one of the most common stages of the natural or surgically induced cessation of
estradiol and progesterone production by the ovaries. It is also a major risk factor for the development of osteoporosis. PCOS is also another common endocrine disorder in
women of reproductive age. Endometriosis is a chronic inflammatory disease observed in women of reproductive age. Postmenopausal osteoporosis is another known
women's health disorder across the globe. It is also known as type I osteoporosis and affects women 45 to 50 years old and above who have gone through menopause.
Attention to women's health disorders has increased dramatically in the past few decades, expanding from a focus on reproductive care to a new, comprehensive life
span approach.
STUDY BACKGROUND
Worldwide an estimated 250 million females suffer from a women's health disorder. However, only 20 million to 25 million female patients are actively receiving treatment
(e.g., hormone therapy/drugs), primarily due to poor diagnosis of the diseases and lack of awareness. There are a few diseases, such as endometriosis, where the cause of the
disease is unknown and thus its treatment remains an intensely debated subject among physicians and patients. There are several treatment options available to obtain
relief from the symptoms of endometriosis but there is no cure. Because of the large patient pool of women's health disorders, there is a pressing need
to develop an up-to-date base of market information to better understand the dynamics of the women's health therapeutics, technologies and global markets.
This report is the first edition to cover the key diseases of women's health market, key growth areas and quantitative market projections for services and devices. Increasing
prevalence and the rising concern of patients toward their health is boosting the women's health market. This study attempts to provide the reader the information and
analysis needed to deal with these challenges.
STUDY GOALS AND OBJECTIVES
This study, Therapeutics for Women's Health: Technologies and Global Markets, provides an overview of products included in this market and detailed analyses of markets and competitive environments. This area covers a wide variety of products and disorders that predominantly affect women. The study includes information about significant products, players, issues and trends, and other information affecting the women's disorders and diseases industry. Our study meets these needs by analyzing global markets for women's health disorders (see the section "Scope" for a definition of these) in light of the most recently available information. In addition to looking at current and future markets, the study will analyze technological, demographic and economic developments that may have a long-term impact on the size and structure of the women's health disorders market.
The future of women's health also will be discussed with forecasts. More specific objectives are to:
- Identify and segment the main women's health disorders and relevant disease prevalence population.
- Analyze the historical and current population under treatment by geographic markets.
- Identify and evaluate the impact of demographic, economic and other factors that will drive future demand for women's health therapeutics market.
- Forecast the disease population targeted for treatment by the probabilities that future demand will be higher or lower than the baseline forecast.
- Identify promising new drugs and therapies still in the development and testing stage and assess the probability they will be commercialized successfully in the next five
years.
- Forecast the potential market based on the pipeline, taking into account the estimated probability they will be commercialized.
- Identify leading drug manufacturers and analyze the structure of the women's health therapeutics industry (e.g., market shares, concentration and recent merger and
acquisition activity).
- Assess the long-term outlook for women's health therapeutics, taking into account market opportunities, as well as technological, financial and economic factors.
Ongoing patient management studies will increase the number of indications. Keeping in touch with these applications for the various products is good business practice. This
study will provide the reader with the knowledge to adequately view and assess the women's healthcare movement and provide insights into the market potential.
INTENDED AUDIENCE
The report has been written for the women's health therapeutics interest community, but is especially tailored for readers with an interest in the marketing and management
dimensions of therapeutics for women's health technologies and global markets. This especially includes readers in the:
- Pharmaceutical and medical industry.
- Medical research institutions.
- Investment community.
- Financial and analyst community.
SCOPE OF THE REPORT
This report is an analytical business tool whose primary purpose is to describe the thorough evaluation of the global market for women's health therapeutics. The format of the study is organized around the following topics:
- Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause and polycystic ovary syndrome (PCOS).
- Disease incidence and prevalence.
- Regulatory structure.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2018.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status and clinical trials.
- Observations and conclusions regarding the future of women's health therapeutics market.
- Profiles of market participants and associations.
METHODOLOGY AND INFORMATION SOURCES
The findings and conclusions of this report are based on information gathered through primary and secondary data collection methods. Primary methods included interviews
with key executives, product managers, clinical specialists and other related key personnel involved in the women's healthcare industry. Secondary sources included
published literature, investment reports, trade publications, trade associations, company literature and online databases and various business journals that have an
emphasis on women's health and related areas to produce the market estimates contained in this report. The base year for analysis and projection is 2012. At the time this report was prepared (early 2014), year-end data for 2013 were not yet universally available.
With 2012 as a baseline, market projections were developed for 2013 to 2018. These projections are based on a consensus of primary contacts combined with BCC Research's understanding of the key market drivers and their impact from a historical and analytical perspective. The analytical methodologies used to generate the market estimates are described in detail in the section on detailed market projections. All dollar projections presented in this report are in 2012 constant dollars.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY BACKGROUND 2
STUDY GOALS AND OBJECTIVES 2
INTENDED AUDIENCE 4
SCOPE OF THE REPORT 4
METHODOLOGY AND INFORMATION SOURCES 4
ANALYST'S CREDENTIALS 5
RELATED BCC RESEARCH REPORTS 5
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 SUMMARY 7
EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS,
THROUGH 2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS,
2012-2018 ($ MILLIONS) 7
CHAPTER 3 OVERVIEW OF WOMEN'S HEALTH DISORDERS 10
DISEASE OVERVIEW AND DEFINITIONS 10
TABLE 1 GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING
FROM A WOMEN'S DISORDER, THROUGH 2018 (MILLIONS) 11
FIGURE 1 DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S
DISORDER BY TYPE, 2012 (% OF TOTAL GENERAL FEMALE POPULATION) 11
HISTORICAL BACKGROUND 12
AGING AND WOMEN'S HEALTH DISORDERS 13
FIGURE 2 FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS
AGE PROGRESSES, 2012 (%) 13
NEW USE FOR CONTRACEPTIVES 15
WOMEN AND SEXUAL HEALTH 17
FEMALE SEXUAL AROUSAL DISORDER 17
FEMALE ORGASMIC DISORDER 18
VAGINISMUS 18
INFERTILITY AND CANCER 18
CHAPTER 4 MENOPAUSE-RELATED SYMPTOMS AND DISEASES 20
OVERVIEW 20
ETIOLOGY 21
EPIDEMIOLOGY AND ECONOMIC BURDEN 21
TABLE 2 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY
GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS) 21
FIGURE 3 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY
GEOGRAPHIC REGION, 2012-2018 (MILLIONS) 21
FIGURE 4 GLOBAL POPULATION OF FEMALES SUFFERING FROM
MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION,
2012-2018 (MILLIONS)
22
FIGURE 5 GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM
MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012 (% OF
GENERAL FEMALE POPULATION)
23
SYMPTOMS OF MENOPAUSE 23
RISK FACTORS FOR EARLY ONSET MENOPAUSE 24
DIAGNOSIS AND TREATMENT 25
DIAGNOSIS OF MENOPAUSE 25
TREATMENT OPTIONS 26
TABLE 3 COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF
MENOPAUSE 26
Premarin (Conjugated Estrogens) 27
Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate
Tablets) 28
Vagifem (Estradiol Vaginal Tablets) 28
Femring (Estradiol Acetate Vaginal Ring) 28
ISSUES ASSOCIATED WITH HORMONE THERAPY 29
REDUCING THE RISK OF EARLY MENOPAUSE 29
CHAPTER 5 POSTMENOPAUSAL OSTEOPOROSIS 32
DISEASE OVERVIEW 32
HUMAN BONE STRUCTURE 32
EPIDEMIOLOGY AND ECONOMIC BURDEN 33
TABLE 4 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY
GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS) 34
FIGURE 6 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY
GEOGRAPHIC REGION, 2012-2018 (MILLIONS) 34
FIGURE 7 GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL
OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2012-2018 (MILLIONS) 34
FIGURE 8 GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL
OSTEOPOROSIS BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION) 35
DISEASE SYMPTOMS AND RISK FACTORS 37
DISEASE SYMPTOMS 37
Fractures 37
Spinal Deformities 37
Pain 37
RISK FACTORS 37
DIAGNOSIS AND TREATMENT 39
DIAGNOSIS OF POSTMENOPAUSAL OSTEOPOROSIS 39
TREATMENT OPTIONS FOR POSTMENOPAUSAL OSTEOPOROSIS 39
Bisphosphonates 40
Hormone Therapy 41
Selective Estrogen Receptor Modulators 41
Calcitonin 42
Parathyroid Hormone 42
TABLE 5 COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL
OSTEOPOROSIS 43
Fosamax (Alendronate Sodium) 43
Actonel (Risedronate Sodium) 44
Evista (Raloxifene Hydrochloride) 45
Boniva (Ibandronate Sodium) 46
Forteo (Teriparatide (rDNA Origin)) Injection 46
Reclast (Zoledronate) 47
Calcitonin (Calcimar, Miacalcin) 47
Forteo (Teriparatide) 48
Aprela (Bazedoxifene/Conjugated Estrogen) 48
Viviant (Bazedoxifene) 48
REDUCING THE RISK OF OSTEOPOROSIS 49
CHAPTER 6 ENDOMETRIOSIS 52
DISEASE OVERVIEW 52
ETIOLOGY AND PATHOPHYSIOLOGY 53
DISEASE SYMPTOMS AND RISK FACTORS 54
PELVIC PAIN 54
DIFFICULTY BECOMING PREGNANT 55
ENDOMETRIOMAS 55
RISK FACTORS 55
Genetic Factors 55
Delayed Pregnancy 55
Age 56
Dietary Factors 56
STAGES OF ENDOMETRIOSIS 56
EPIDEMIOLOGY AND ECONOMIC BURDEN 57
TABLE 6 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, THROUGH
2018 (MILLIONS) 58
FIGURE 9 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, 2012-2018
(MILLIONS) 58
FIGURE 10 GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE
POPULATION, 2012-2018 (MILLIONS) 59
FIGURE 11 GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY
GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION) 59
DIAGNOSIS AND TREATMENT 60
DIAGNOSIS OF ENDOMETRIOSIS 60
Pelvic Exam 61
Laparoscopy 61
Other Diagnostic Procedures 61
TREATMENT OPTIONS FOR ENDOMETRIOSIS 62
Pharmacological Treatment 62
NSAIDs 62
Hormonal Birth Control Treatments 63
Progestins 64
Gonadotropin Releasing Hormone Agonists 64
TABLE 7 DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS 65
Zoladex 65
Lupron Depot (Leuprolide Acetate) 66
Synarel (Nafarelin Acetate) 66
Danazol 66
Visanne 66
Surgery 67
LOWERING THE RISK OF ENDOMETRIOSIS 68
CHAPTER 7 POLYCYSTIC OVARY SYNDROME 70
DISEASE OVERVIEW 70
ETIOLOGY 70
EPIDEMIOLOGY AND ECONOMIC BURDEN 71
TABLE 8 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC
REGION, THROUGH 2018 (MILLIONS) 72
FIGURE 12 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC
REGION, 2012-2018 (MILLIONS) 72
FIGURE 13 GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS
FEMALE POPULATION, 2012-2018 (MILLIONS) 72
FIGURE 14 GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME
POPULATION BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION) 73
DISEASE SYMPTOMS AND RISK FACTORS 74
DIAGNOSIS AND TREATMENT 75
DIAGNOSIS OF PCOS 75
Medical History and Physical Examination 75
Pelvic Examination 75
Laboratory Testing 75
Imaging Tests 76
TREATMENT OPTIONS FOR POLYCYSTIC OVARY SYNDROME 76
TABLE 9 COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF
POLYCYSTIC OVARY SYNDROME 77
Medications 78
Clomid (Clomiphene) 78
Vaniqa (Eflornithine) 79
Glucophage (Metformin) 79
Actos (Pioglitazone) and Avandia (Rosiglitazone) 79
Aldactone (Spironolactone) 79
Precose (Acarbose) 79
Apri (Desogestrel/Ethinyl Estradiol) 79
Propecia (Finasteride) 80
Eulexin (Flutamide) 80
Femara (Letrozole) 80
REDUCING THE RISK OF PCOS 80
CHAPTER 8 WOMEN'S HEALTH DISORDER THERAPEUTICS MARKET ASSESSMENT 82
GLOBAL WOMEN'S HEALTH MARKET 82
FIGURE 15 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY GEOGRAPHIC
REGION, 2012-2018 ($ MILLIONS) 82
FIGURE 16 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE,
2012-2018 ($ MILLIONS) 83
FIGURE 17 GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS
MARKET BY DISORDER TYPE, 2012 (%) 84
FIGURE 18 AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH
DISORDER, 2012-2018 ($) 85
ENDOMETRIOSIS 86
FIGURE 19 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY GEOGRAPHIC
REGION, 2012-2018 ($ MILLIONS) 86
MENOPAUSE 87
FIGURE 20 GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED
CONDITIONS BY GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS) 87
POSTMENOPAUSAL OSTEOPOROSIS 88
FIGURE 21 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY
GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS) 88
POLYCYSTIC OVARY SYNDROME 90
FIGURE 22 GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS
BY GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS) 90
ANNUAL COST OF THERAPY 91
FIGURE 23 GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER,
2012-2018 ($) 91
GENERICS VERSUS BRANDED 92
FIGURE 24 GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET:
BRANDED VS. GENERIC, 2012 (%) 93
MARKET GROWTH DRIVERS AND RESTRAINTS 93
Growth Drivers for Menopause-Related Conditions 93
Aging Female Population 93
Growth Restraints for Menopause 94
Low Rate of Prescriptions for Hormone Therapy 94
Availability of Alternative Treatment Options 94
Lack of Safe and Efficacious Drug 94
Growth Drivers for Endometriosis 94
Increasing Awareness 94
Growth Restraints for Endometriosis 95
Poor Diagnosis 95
Absence of Non-hormonal Therapy 95
Growth Drivers for Postmenopausal Osteoporosis 96
Increasing Disease Population 96
Sedentary Lifestyle 96
Growth Restraints for Postmenopausal Osteoporosis 96
Poor Diagnosis 96
Growth Drivers for PCOS 97
Growing Treated Population 97
Growth Restraints for PCOS 97
Unavailability of Novel Drugs 97
CHAPTER 9 COMPETITION AND MARKET SHARES 99
TABLE 10 LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH
THERAPEUTICS, 2012 ($ MILLIONS/%) 99
FIGURE 25 GLOBAL MARKET LEADER SHARES OF WOMEN'S HEALTH
THERAPEUTICS MARKET, 2012 (%) 99
CHAPTER 10 MARKET STRATEGY 102
TABLE 11 KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET 102
MERGERS AND ACQUISITIONS 103
ACTAVIS' ACQUISITION OF WARNER CHILCOTT 103
AMGEN'S ACQUISITION OF MUSTAFA NEVZAT (MN) PHARMACEUTICALS 103
VALEANT PHARMACEUTICALS' ACQUISITION OF INOVA 103
TAKEDA'S ACQUISITION OF NYCOMED 104
TEVA PHARMACEUTICAL'S ACQUISITION OF THERAMEX 104
THERAPEUTICSMD'S ACQUISITION OF VITAMEDMD 104
SANOFI-AVENTIS' ACQUISITION OF BMP SUNSTONE 104
ABBOTT'S ACQUISITION OF SOLVAY PHARMACEUTICALS 105
FERRING PHARMACEUTICALS' ACQUIRED GLOBAL RIGHTS TO LYSTEDA
FROM XANODYNE PHARMACEUTICALS 105
BIOSANTE ACQUIRED ELESTRIN ROYALTY FROM AZUR PHARMA 105
TEVA-KOWA PHARMA ACQUIRED MAJORITY STAKE IN TAISHO
PHARMACEUTICAL 106
SCIELE PHARMA'S ACQUISTION OF ADDRENEX PHARMACEUTICALS 106
WARNER CHILCOTT'S ACQUISITION OF PROCTER & GAMBLE'S
PRESCRIPTION DRUG BUSINESS 106
BIOSANTE PHARMACEUTICALS MERGES WITH CELL GENESYS 107
HISAMITSU PHARMACEUTICAL'S ACQUISITION OF NOVEN
PHARMACEUTICALS 107
PFIZER'S ACQUISITION OF WYETH 107
PAR PHARMACEUTICALS' ACQUISITION OF MDRNA'S CALCITONIN ASSETS
AND MANUFACTURING FACILITY 107
CHAPTER 11 DRUG PIPELINE ANALYSIS 110
TABLE 12 PIPELINE DRUGS IN WOMEN'S HEALTH 110
DRUGS UNDER DEVELOPMENT 112
TAK-385 (RELUGOLIX) 112
Description 112
Safety/Efficacy 112
Clinical Trials 112
ELAGOLIX 113
Description 113
Safety/Efficacy 113
Clinical Trials 114
ASP1707 115
Description 115
Clinical Trials 115
PROELLEX (TELAPRISTONE ACETATE) (6 MG AND 12 MG, LOW DOSE ORAL) 116
Description 116
Safety/Efficacy 116
Low Dose Oral Study 117
Vaginal Administration 117
PGL2001 (PGL2) 118
Description 118
Safety/Efficacy 118
Clinical Trials 118
PGL5001 (PGL5) (BENTAMAPIMOD/PROOF OF CONCEPT) 118
Description 118
Clinical Trials 119
KLH-2109 119
Description 119
Clinical Trials 119
AUS-131 (S-EQUOL) 119
Description 119
Safety/Efficacy 119
Clinical Trials 120
MPI-676 AND MPI-674 (FEMATHINA) 120
Description 120
Clinical Trials 121
17HSD1 (17-BETA-HYDROXYSTEROID DEHYDROGENASE 1) 121
Description 121
Safety/Efficacy 122
Clinical Trials 122
FEMITRA (ACOLBIFENE + DHEA (ORAL) + GNRH AGONIST)
(SUBCUTANEOUS) 122
Description 122
BAY 1026153 123
Description 123
MK-0822 (ODANACATIB) 123
Description 123
Safety and Efficacy 123
Clinical Trials 123
MENERBA 124
Description 124
Safety/Efficacy 125
Clinical Trials 125
SEALA 126
Description 126
Clinical Trials 126
BA058-SC (ABALOPARATIDE) 127
Description 127
Safety/Efficacy 127
Clinical Trials 127
BA058-TD (TRANSDERMAL DELIVERY) 129
Description 129
Safety/Efficacy 129
Clinical Trials 130
RAD1901 130
Description 130
Safety/Efficacy 131
Clinical Trials 131
ZP-PTH (TERIPARATIDE) 132
Description 132
Safety/Efficacy 132
Clinical Trials 132
RECOMBINANT ORAL SALMON CALCITONIN 133
Description 133
Safety/Efficacy 133
Clinical Trials 133
ESN364 134
Description 134
Safety/Efficacy 134
Clinical Trials 134
VAGINORM 134
Description 134
Clinical Trials 135
AZD4901 135
Description 135
Clinical Trials 135
ESTRADIOL + TESTOSTERONE GEL 135
Description 135
AMG 785/CDP7851 (ROMOSOZUMAB) 135
Description 135
Safety/Efficacy 136
Clinical Trials 136
TX 12-001HR (17B ESTRADIOL + PROGESTERONE) 137
Description 137
Clinical Trials 137
CHAPTER 12 REGULATORY STRUCTURE 139
UNITED STATES 139
EUROPE 140
REGULATORY PROCEDURES 141
National Authorization Procedure 141
Centralized Procedure 141
Decentralized Procedure 141
Mutual Recognition Procedure 141
JAPAN 141
CHAPTER 13 PRICING AND REIMBURSEMENT 145
UNITED STATES 145
EUROPE 147
JAPAN 148
CHAPTER 14 CONCLUSIONS-OUTLOOK FOR WOMEN'S HEALTH THERAPEUTICS 150
MAJOR DEVELOPMENTS TO INFLUENCE MARKET 150
THERAPEUTIC DEVELOPMENTS 150
DEMOGRAPHIC AND ECONOMIC TRENDS 151
Increasing Aging Population 151
TABLE 13 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND
PROJECTIONS BY GENDER, 2005-2020 (YEARS) 152
FIGURE 26 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND
PROJECTIONS BY GENDER, 2005-2020 (YEARS) 152
TABLE 14 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030
(MILLIONS) 153
FIGURE 27 PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030
(MILLIONS) 153
TABLE 15 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 154
FIGURE 28 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 154
TABLE 16 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030
(MILLIONS) 155
FIGURE 29 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000–2030
(MILLIONS) 155
TABLE 17 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000–2030 (MILLIONS) 156
FIGURE 30 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 156
Income Growth in Developing Markets 156
TABLE 18 PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION,
2012-2015 (ANNUAL AVERAGE PERCENTAGE CHANGE) 157
TRENDS IN REIMBURSEMENT 157
FUTURE OUTLOOK 158
CHAPTER 15 APPENDIX A: COMPANY PROFILES 160
ABBVIE 160
ACTAVIS 160
AMGEN 161
ASAHI KASAI 162
ASTRAZANECA 162
ASTELLAS PHARMA INC. 163
BAYER 163
BIONOVO 164
CHUGAI PHARMACEUTICALS 165
DEPOMED INC. 165
ELI LILLY 166
ENDOCEUTICS 166
FORENDO PHARMA OY 167
IPSEN SA 168
LES LABORATORIES SERVIER SAS 168
MERCK 169
MOCHIDA PHARMA CO. LTD. 170
MEDITRINA PHARMACEUTICALS INC. 170
NOVARTIS AG 171
NOVO NORDISK A/S 172
NOVOGYNE PHARMACEUTICALS 173
NEUROCRINE BIOSCIENCES INC. 173
ORION PHARMA LTD. 173
PALADIN LABS INC. 174
PFIZER INC. 174
PREGLEM SA 176
ROCHE 176
RADIUS HEALTH INC. 177
REPROS THERAPEUTICS INC. 178
TAKEDA PHARMACEUTICAL 178
TEVA PHARMACEUTICAL INDUSTRIES 178
TSUMURA & CO. 179
TARSA THERAPEUTICS INC. 180
THERAPEUTICSMD 180
WARNER CHILCOTT CORP. 180
ZOSANO PHARMA INC. 181
CHAPTER 16 APPENDIX B: INDUSTRY AND PROFESSIONAL ORGANIZATIONS 184
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM) 184
ANDROGEN EXCESS AND PCOS SOCIETY 184
ASIA-PACIFIC MENOPAUSE FEDERATION 184
ENDOMETRIOSIS ASSOCIATION 184
ENDOMETRIOSIS FOUNDATION OF AMERICA (EFA) 184
ENDOMETRIOSIS.ORG 185
ENDOMETRIOSIS RESEARCH CENTRE (ERC) 185
ENDOMETRIOSIS U.K. 185
EUROPEAN ENDOMETRIOSIS LEAGUE (EEL) 185
EUROPEAN MENOPAUSE AND ANDROPAUSE SOCIETY (EMAS) 186
EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY (ESHRE) 186
FOOD AND DRUG ADMINISTRATION (FDA) 186
HORMONE FOUNDATION 186
INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS &
ASSOCIATIONS (IFPMA) 187
INTERNATIONAL MENOPAUSE SOCIETY (IMS) 187
INTERNATIONAL OSTEOPOROSIS FOUNDATION (IOF) 187
JAPAN ENDOMETRIOSIS ASSOCIATION (JEMA) 187
JAPAN SOCIETY FOR MENOPAUSE AND WOMEN'S HEALTH 188
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION (NCBI) 188
NATIONAL INSTITUTE ON AGING (NIA) 188
NORTH AMERICAN MENOPAUSE SOCIETY (NAMS) 188
NATIONAL OSTEOPOROSIS FOUNDATION (NOF) 189
NATIONAL WOMEN'S HEALTH INFORMATION CENTER (NWHIC) 189
PCOSUPPORT 189
WORLD ENDOMETRIOSIS RESEARCH FOUNDATION (WERF) 189
CHAPTER 17 APPENDIX C: ACTIVE CLINICAL TRIALS 191
TABLE 19 ENDOMETRIOSIS TRIALS 191
TABLE 20 MENOPAUSE TRIALS 192
TABLE 21 POLYCYSTIC OVARY SYNDROME (PCOS) TRIALS 194
TABLE 22 POST MENOPAUSAL OSTEOPOROSIS TRIALS 195
CHAPTER 18 APPENDIX D: ABBREVIATIONS 200
ABBREVIATIONS 200
LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS,
THROUGH 2018 ($ MILLIONS) 7
TABLE 1 GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM
A WOMEN'S DISORDER, THROUGH 2018 (MILLIONS) 11
TABLE 2 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY
GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS) 21
TABLE 3 COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF
MENOPAUSE 26
TABLE 4 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY
GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS) 34
TABLE 5 COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL
OSTEOPOROSIS 43
TABLE 6 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, THROUGH
2018 (MILLIONS) 58
TABLE 7 DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS 65
TABLE 8 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC REGION,
THROUGH 2018 (MILLIONS) 72
TABLE 9 COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF
POLYCYSTIC OVARY SYNDROME 77
TABLE 10 LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH
THERAPEUTICS, 2012 ($ MILLIONS/%) 99
TABLE 11 KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET 102
TABLE 12 PIPELINE DRUGS IN WOMEN'S HEALTH 110
TABLE 13 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND
PROJECTIONS BY GENDER, 2005-2020 (YEARS) 152
TABLE 14 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030
(MILLIONS) 153
TABLE 15 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 154
TABLE 16 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030
(MILLIONS) 155
TABLE 17 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000–2030 (MILLIONS) 156
TABLE 18 PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION,
2012-2015 (ANNUAL AVERAGE PERCENTAGE CHANGE) 157
TABLE 19 ENDOMETRIOSIS TRIALS 191
TABLE 20 MENOPAUSE TRIALS 192
TABLE 21 POLYCYSTIC OVARY SYNDROME (PCOS) TRIALS 194
TABLE 22 POST MENOPAUSAL OSTEOPOROSIS TRIALS 195
LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS,
2012-2018 ($ MILLIONS) 7
FIGURE 1 DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S
DISORDER BY TYPE, 2012 (% OF TOTAL GENERAL FEMALE POPULATION) 11
FIGURE 2 FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS
AGE PROGRESSES, 2012 (%) 13
FIGURE 3 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY
GEOGRAPHIC REGION, 2012-2018 (MILLIONS) 21
FIGURE 4 GLOBAL POPULATION OF FEMALES SUFFERING FROM
MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION,
2012-2018 (MILLIONS)
22
FIGURE 5 GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM
MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012 (% OF GENERAL
FEMALE POPULATION)
23
FIGURE 6 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY
GEOGRAPHIC REGION, 2012-2018 (MILLIONS) 34
FIGURE 7 GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL
OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2012-2018 (MILLIONS) 34
FIGURE 8 GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL
OSTEOPOROSIS BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION) 35
FIGURE 9 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, 2012-2018
(MILLIONS) 58
FIGURE 10 GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE
POPULATION, 2012-2018 (MILLIONS) 59
FIGURE 11 GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY
GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION) 59
FIGURE 12 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC
REGION, 2012-2018 (MILLIONS) 72
FIGURE 13 GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS
FEMALE POPULATION, 2012-2018 (MILLIONS) 72
FIGURE 14 GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION
BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION) 73
FIGURE 15 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY GEOGRAPHIC
REGION, 2012-2018 ($ MILLIONS) 82
FIGURE 16 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE,
2012-2018 ($ MILLIONS) 83
FIGURE 17 GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET
BY DISORDER TYPE, 2012 (%) 84
FIGURE 18 AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDER,
2012-2018 ($) 85
FIGURE 19 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY GEOGRAPHIC
REGION, 2012-2018 ($ MILLIONS) 86
FIGURE 20 GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED
CONDITIONS BY GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS) 87
FIGURE 21 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY
GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS) 88
FIGURE 22 GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY
GEOGRAPHIC REGION, 2012-2018 ($ MILLIONS) 90
FIGURE 23 GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2012-2018
($) 91
FIGURE 24 GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET:
BRANDED VS. GENERIC, 2012 (%) 93
FIGURE 25 GLOBAL MARKET LEADER SHARES OF WOMEN'S HEALTH THERAPEUTICS
MARKET, 2012 (%) 99
FIGURE 26 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND
PROJECTIONS BY GENDER, 2005-2020 (YEARS) 152
FIGURE 27 PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 153
FIGURE 28 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 154
FIGURE 29 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000–2030
(MILLIONS) 155
FIGURE 30 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS) 156
To order this report: Therapeutics for Women%s Health: Technologies and Global Markets
http://www.reportlinker.com/p02158721/Therapeutics-for-Women%s-Health-Technologies-and-Global-Markets.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article